Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein

By Gorse G.J.   Patel G.B.   Newman F.K.   Mandava M.   Belshe R.B.  

Vaccine, Vol. 13, Iss. 13, 1995-01 ,pp. : 1170-1179

Elsevier

Access to resources Recommend Favorite

HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva

By NIAID AIDS   Gorse G.J.   Rogers J.H.   Perry J.E.   Newman F.K.   Frey S.E.   Patel G.B.   Belshe R.B.  

Vaccine, Vol. 13, Iss. 2, 1995-02 ,pp. : 209-214

Elsevier

Access to resources Recommend Favorite

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

By Barnett S.W.   Rajasekar S.   Legg H.   Doe B.   Fuller D.H.   Haynes J.R.   Walker C.M.   Steimer K.S.  

Vaccine, Vol. 15, Iss. 8, 1997-06 ,pp. : 869-873

Elsevier

Access to resources Recommend Favorite

Apoptosis in asymptomatic HIV-1 seropositives immunized with HIV-1 env glycoprotein (gp160): Effects of administration of Zidovudine in vivo and interleukin-2 in vitro

By Pierdominici M.   Mollicone B.   Ricci G.   Oliva A.   D'Offizi G.   Giovannetti A.   Aiuti F.   Pandolfi F.  

Vaccine, Vol. 16, Iss. 7, 1998-04 ,pp. : 715-721

Elsevier

Access to resources Recommend Favorite

Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies

By Jones D.H.   McBride B.W.   Roff M.A.   Farrar G.H.  

Vaccine, Vol. 13, Iss. 11, 1995-01 ,pp. : 991-999

Elsevier

Access to resources Recommend Favorite